Inovio Pharmaceuticals' (INO) "Neutral" Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Inovio Pharmaceuticals (NASDAQ:INO - Free Report) in a research report sent to investors on Wednesday,Benzinga reports. The firm currently has a $3.00 price objective on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Inovio Pharmaceuticals' Q1 2025 earnings at ($0.75) EPS, Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($2.12) EPS.

Separately, JMP Securities restated a "market outperform" rating and issued a $18.00 price objective on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $12.20.

Inovio Pharmaceuticals Stock Performance

INO traded down $0.02 on Wednesday, hitting $1.92. 2,019,265 shares of the company were exchanged, compared to its average volume of 550,650. The stock's fifty day moving average is $2.04 and its 200-day moving average is $3.67. The company has a market cap of $50.11 million, a PE ratio of -0.48 and a beta of 0.92. Inovio Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $14.75.

Remove Ads

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last released its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.18. The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, equities research analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of Inovio Pharmaceuticals by 6.7% in the third quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company's stock valued at $3,594,000 after purchasing an additional 38,833 shares during the last quarter. Barclays PLC grew its position in shares of Inovio Pharmaceuticals by 282.6% in the third quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company's stock valued at $197,000 after purchasing an additional 25,116 shares during the last quarter. FMR LLC grew its position in shares of Inovio Pharmaceuticals by 370.1% in the third quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company's stock valued at $158,000 after purchasing an additional 21,462 shares during the last quarter. State Street Corp grew its position in Inovio Pharmaceuticals by 11.7% during the third quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company's stock worth $2,836,000 after buying an additional 51,414 shares in the last quarter. Finally, Green Alpha Advisors LLC grew its position in Inovio Pharmaceuticals by 103.2% during the fourth quarter. Green Alpha Advisors LLC now owns 65,446 shares of the biopharmaceutical company's stock worth $120,000 after buying an additional 33,232 shares in the last quarter. Institutional investors and hedge funds own 26.79% of the company's stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.